Ga Syfovre denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Step Therapy to Syfovre — and How to Appeal

For Syfovre (pegcetacoplan) in geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a step-therapy denial from Aetna typically indicates that the plan's Clinical Policy Bulletin requires documentation that the patient has previously tried or been evaluated for another covered agent — most often Izervay (avacincaptad pegol), the other FDA-approved intravitreal therapy for GA — or, less commonly, a more general requirement for documented monitoring and conservative management prior to initiating intravitreal anti-complement therapy.

## Why This Denial Is Appealable

GA is a progressive, irreversible condition. Both FDA-approved intravitreal anti-complement agents for GA are first-in-class drugs — there is no established, broadly accepted prior-therapy standard analogous to step therapy in other therapeutic areas. If Aetna's step-therapy requirement demands trial of a prior agent that is not clinically differentiated for this patient, or if clinical urgency exists given the rate of GA progression, a step-therapy exception is the appropriate vehicle. Many states and federal guidelines include step-therapy exception rights when the required prior treatment is not appropriate or when delay would cause harm.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: Step-therapy denials are subject to full-and-fair internal review. You are entitled to the specific step-therapy protocol Aetna applied.
• Step-Therapy Exception Rights: Most states have enacted laws requiring insurers to grant exceptions when the required prior therapy is contraindicated, clinically inappropriate, or would cause harm. Federal law under ERISA requires that step-therapy protocols be based on sound clinical standards.
• External Review: If the internal appeal or exception request is denied, you may request IRO review. The standard external review window is approximately four months from the final internal denial. Expedited review is available when delay would seriously jeopardize vision.

## Appeal Timeline

1. Obtain the denial letter and identify the exact step(s) Aetna claims were not completed. 2. Determine whether a step-therapy exception is warranted given the clinical circumstances. 3. Submit the internal appeal or exception request with the documentation below. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: Retinal imaging confirming GA secondary to AMD, including lesion characteristics and progression rate — which supports the urgency of initiating treatment.
• Prior-treatment or evaluation history: Documentation of any prior ocular treatments or evaluations, and the clinical rationale for selecting Syfovre rather than the alternative FDA-approved GA agent.
• Prescriber medical-necessity letter: Your retina specialist should address each step-therapy requirement, explain the clinical rationale for the chosen agent, and — if applicable — document why the required prior step is clinically inappropriate, would cause harm, or has already been evaluated and rejected for individualized clinical reasons.
• Step-therapy exception basis: If applicable, cite the state step-therapy exception law or plan exception language and the clinical facts that satisfy it.

## Criteria-Mapping Strategy

Obtain the current Aetna Clinical Policy Bulletin for Syfovre and any step-therapy addendum. List each required prior step and your response to it. If the required prior agent is clinically equivalent and no exception applies, document the clinical reasoning for Syfovre preference. If an exception applies, build the exception argument as the primary basis. Reference the FDA-approved prescribing information for Syfovre and the applicable professional society guidance (such as from the American Academy of Ophthalmology) by organization name to demonstrate that selecting Syfovre is consistent with evidence-based practice for this patient's specific presentation.